TETTAMANTI, SARAH
 Distribuzione geografica
Continente #
NA - Nord America 2.874
AS - Asia 1.888
EU - Europa 1.824
SA - Sud America 306
AF - Africa 50
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.953
Nazione #
US - Stati Uniti d'America 2.774
SG - Singapore 728
IT - Italia 662
CN - Cina 436
BR - Brasile 257
HK - Hong Kong 237
RU - Federazione Russa 230
DE - Germania 224
IE - Irlanda 188
VN - Vietnam 161
SE - Svezia 134
GB - Regno Unito 94
CA - Canada 72
IN - India 70
ID - Indonesia 63
FR - Francia 53
FI - Finlandia 39
PL - Polonia 35
KR - Corea 33
ZA - Sudafrica 29
JP - Giappone 27
NL - Olanda 25
ES - Italia 23
AT - Austria 22
TR - Turchia 22
PK - Pakistan 21
MX - Messico 20
UA - Ucraina 20
AR - Argentina 16
IR - Iran 16
BE - Belgio 15
BD - Bangladesh 14
DK - Danimarca 13
IQ - Iraq 12
CH - Svizzera 10
RO - Romania 8
AU - Australia 7
IL - Israele 7
LT - Lituania 7
TW - Taiwan 7
EG - Egitto 6
NP - Nepal 6
PE - Perù 6
CZ - Repubblica Ceca 5
EC - Ecuador 5
KZ - Kazakistan 5
MA - Marocco 5
PH - Filippine 5
CI - Costa d'Avorio 4
CL - Cile 4
CO - Colombia 4
NO - Norvegia 4
PY - Paraguay 4
RS - Serbia 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
JM - Giamaica 3
LB - Libano 3
UY - Uruguay 3
UZ - Uzbekistan 3
AM - Armenia 2
BO - Bolivia 2
DZ - Algeria 2
HR - Croazia 2
KE - Kenya 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BB - Barbados 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
RE - Reunion 1
TH - Thailandia 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 6.953
Città #
Singapore 430
Ann Arbor 429
Ashburn 392
Hong Kong 234
Milan 214
Chandler 186
Dublin 182
Frankfurt am Main 129
Fairfield 114
New York 100
Los Angeles 84
Wilmington 78
Beijing 77
Seattle 76
Hefei 72
Dallas 69
Houston 67
Woodbridge 62
Santa Clara 59
Ho Chi Minh City 57
Jakarta 51
Shanghai 48
Cambridge 47
Bergamo 42
The Dalles 40
Denver 39
Princeton 37
Hanoi 32
Munich 32
São Paulo 32
Buffalo 30
Montreal 30
Chicago 29
Dearborn 28
Seoul 27
Tokyo 25
Warsaw 23
Johannesburg 22
Lissone 22
Nanjing 22
Moscow 20
Orem 19
Poplar 16
Altamura 15
Brussels 15
Helsinki 15
London 15
Stockholm 15
Paris 14
Lawrence 13
Monza 13
Rome 13
Brooklyn 12
Lappeenranta 12
Vienna 12
Atlanta 11
Borgomanero 11
Desio 11
Genoa 11
Jacksonville 11
Lahore 11
Manchester 11
Mumbai 11
Nuremberg 11
Toronto 11
Turin 11
Ankara 10
Carate Brianza 10
Carrboro 10
Cinisello Balsamo 10
Council Bluffs 10
Hyderabad 10
Seregno 10
Boston 9
Phoenix 9
Turku 9
Andover 8
Bologna 8
Chennai 8
Fremont 8
Kent 8
Belo Horizonte 7
Brasília 7
Hangzhou 7
Mexico City 7
Ottawa 7
Wroclaw 7
Brescia 6
Düsseldorf 6
Galliate 6
Guangzhou 6
Jinan 6
Missaglia 6
Naples 6
New Delhi 6
Pune 6
Rio de Janeiro 6
San Francisco 6
Zhengzhou 6
Calgary 5
Totale 4.365
Nome #
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 394
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 374
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 356
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 352
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 345
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 304
Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going? 296
CXCR4-MODIFIED CD33.CAR-CIK WITH ENHANCED BONE MARROW HOMING IN ACUTE MYELOID LEUKEMIA 279
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden 236
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 226
Catch me if you can: how AML and its niche escape immunotherapy 224
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use 221
Overexpression of CXCR4 receptor on CD33.CAR-CIK cells enhances the control of the Acute Myeloid Leukemia burden 211
Update on: proteome analysis in thyroid pathology - part II: overview of technical and clinical enhancement of proteomic investigation of the thyroid lesions 210
Cellule CD33.CAR-CIK ingegnerizzate per co-esprimere il recettore CXCR4 al fine di aumentare la capacità di migrazione all’interno della nicchia midollare nella leucemia mieloide acuta 204
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 203
Combining the Expression of CD33.CAR and CXCR4 to Increase CAR-CIK Cell Homing to Bone Marrow Niche and Leukemic Stem Cell Eradication in Acute Myeloid Leukemia 202
Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions 198
Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia 194
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 193
Combining the expression of CD33.CAR and CXCR4 to augment CAR-CIKs homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia 188
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 184
Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche 177
Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability 175
Generation of CIK cells co-expressing CXCR4 and CD33.CAR with improved homing and antitumor activity for AML 173
CARs are sharpening their weapons 166
Improving Bone Marrow Homing and Persistence of CD33.CAR-CIK Cells By Overexpression of a Gain-of-Function Variant of CXCR4 to Increase Efficacy in Acute Myeloid Leukemia 164
The management of haemoglobin interference for the MALDI-MSI analysis of in-vivo thyroid biopsies 159
Ingegnerizzazione di cellule CD33.CAR-CIK con una variante gain-of-function del recettore CXCR4 per aumentarne migrazione e persistenza nella nicchia midollare 140
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies 138
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab 135
Acute Myeloid Leukemia (AML) immunotherapy: development of TIM3-CD33 targeted Dual CAR CIK cells for eradication of LSCs in the bone marrow niche 124
Totale 7.145
Categoria #
all - tutte 22.653
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.653


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021293 0 0 0 0 0 62 39 46 33 43 29 41
2021/2022335 23 33 22 18 20 18 11 15 24 32 24 95
2022/2023703 91 164 69 65 16 93 19 51 49 4 58 24
2023/2024723 31 29 45 59 72 171 117 46 59 19 14 61
2024/20251.639 62 111 134 65 109 103 125 74 150 247 165 294
2025/20262.573 569 249 315 617 618 205 0 0 0 0 0 0
Totale 7.145